Trillium Asset Management LLC Has $23.31 Million Position in Stryker Co. (NYSE:SYK)

Trillium Asset Management LLC boosted its position in Stryker Co. (NYSE:SYK) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,839 shares of the medical technology company’s stock after purchasing an additional 5,796 shares during the period. Trillium Asset Management LLC’s holdings in Stryker were worth $23,309,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Manhattan West Asset Management LLC increased its stake in shares of Stryker by 29.1% in the third quarter. Manhattan West Asset Management LLC now owns 1,230 shares of the medical technology company’s stock valued at $324,000 after buying an additional 277 shares during the period. Annex Advisory Services LLC grew its stake in Stryker by 4.5% during the third quarter. Annex Advisory Services LLC now owns 1,589 shares of the medical technology company’s stock worth $434,000 after purchasing an additional 69 shares during the period. Wealthfront Advisers LLC grew its stake in Stryker by 8.0% during the third quarter. Wealthfront Advisers LLC now owns 37,257 shares of the medical technology company’s stock worth $10,181,000 after purchasing an additional 2,771 shares during the period. Centerpoint Advisors LLC grew its stake in Stryker by 16.7% during the third quarter. Centerpoint Advisors LLC now owns 1,750 shares of the medical technology company’s stock worth $478,000 after purchasing an additional 250 shares during the period. Finally, New Mexico Educational Retirement Board grew its stake in Stryker by 7.3% during the third quarter. New Mexico Educational Retirement Board now owns 17,609 shares of the medical technology company’s stock worth $4,812,000 after purchasing an additional 1,200 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK traded up $0.70 during trading hours on Friday, reaching $334.68. The stock had a trading volume of 940,474 shares, compared to its average volume of 1,622,308. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. The stock has a 50 day simple moving average of $342.20 and a 200 day simple moving average of $321.84. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The stock has a market cap of $127.50 billion, a P/E ratio of 38.21, a price-to-earnings-growth ratio of 2.61 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.14 earnings per share. On average, research analysts forecast that Stryker Co. will post 11.94 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Friday, June 28th. Stryker’s dividend payout ratio is 36.53%.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on SYK shares. Truist Financial raised their target price on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Barclays raised their target price on Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Roth Mkm increased their price target on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Citigroup increased their price target on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Stifel Nicolaus increased their price target on Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $365.94.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.